Clindamycin phosphate and benzoyl peroxide gel for acne treatment in patients 12 years and older

Clindamycin phosphate and benzoyl peroxide gel is a topical medication combining an antibiotic and a keratolytic agent, used to treat acne vulgaris in individuals aged 12 and older. It comes as a gel formulation containing 1.2% clindamycin phosphate and 3.75% benzoyl peroxide. This treatment targets bacteria associated with acne and helps improve skin condition through antibacterial and keratolytic effects.

This gel is approved for the treatment of acne vulgaris in patients who are 12 years of age or older. It is intended for topical use on the skin and should not be used orally, ophthalmically, or intravaginally.

Clindamycin phosphate, benzoyl peroxide

Clindamycin phosphate is an antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunits, which prevents the growth of bacteria, including Propionibacterium acnes involved in acne. Benzoyl peroxide acts as an oxidizing agent with bactericidal and keratolytic properties, helping to reduce bacteria and encourage peeling of the skin, though its exact mechanism is not fully understood.

Before applying, gently wash the face with a mild soap, rinse thoroughly with warm water, and pat dry. Apply a pea-sized amount of the gel once daily to the affected area on the face, avoiding contact with eyes, mouth, mucous membranes, or broken skin. The safety of use beyond 12 weeks has not been established.

• Known hypersensitivity to clindamycin, benzoyl peroxide, lincomycin, or any components of the formulation.
• Patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

• Colitis risk: Clindamycin can cause severe colitis, including pseudomembranous colitis, which may be fatal. If significant diarrhea or bloody diarrhea occurs, discontinue use immediately and seek medical advice.
• Sun exposure: Minimize exposure to sunlight, tanning beds, or sun lamps while using this medication, as it may increase skin sensitivity.
• Concomitant topical medications: Use caution when combining with other topical acne treatments that may cause irritation. If dermatitis or significant irritation develops, reduce application frequency or stop treatment temporarily.
• Hypersensitivity: Do not use if you have a known allergy to clindamycin, benzoyl peroxide, lincomycin, or any gel components due to risk of severe allergic reactions including anaphylaxis.

The most commonly reported side effects occur in fewer than 0.5% of patients and include burning sensation, contact dermatitis, itching, and rash. Local skin reactions such as erythema, scaling, itching, burning, and stinging may peak around four weeks of use but often improve by week twelve.

Postmarketing reports include rare cases of serious allergic reactions leading to hospitalization, including anaphylaxis.

• Avoid use with topical or oral erythromycin products due to possible antagonistic effects with clindamycin.
• Use caution if receiving neuromuscular blocking agents, as clindamycin may enhance their effects.

Pregnancy

There are no adequate data to determine the risk of clindamycin phosphate and benzoyl peroxide gel in pregnant women. Limited published data on clindamycin use during pregnancy do not show increased risk of birth defects. Animal studies showed no embryo-fetal toxicity at doses much higher than human exposure.

Lactation

It is unknown whether clindamycin or benzoyl peroxide is excreted in human milk following topical use. Clindamycin is found in small amounts in breast milk after systemic use. If applied to the chest during breastfeeding, care should be taken to prevent infant ingestion.